CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be? .......... 560
M. Ladanyi
Commentary on Cheung et al., p. 608

REVIEW
PI3Kα Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic .......... 562
D.A. Fruman and C. Rammel

RESEARCH BRIEFS
Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence .......... 573

Précis: An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with MET gene polysomy and autocrine HGF production.

A Novel Platform for Detection of CK⁺ and CK⁻ CTCs ............. 580

Précis: An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies nonepithelial CTCs.

IN THIS ISSUE
Highlighted research articles................. vi

NEWS IN BRIEF
Important news stories affecting the community .......... 541

NEWS IN DEPTH
Q&A: William Sellers on Success in Small Molecules .......... 543
Upcoming Battles in the War on Cancer ................. 544

RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature ............ 547

ONLINE
For more News and Research Watch, visit Cancer Discovery online at www.AACR.org/CDnews.

VIEWS
In The Spotlight

Anti-MET Targeted Therapy Has Come of Age: The First Durable Complete Response with MetMAB in Metastatic Gastric Cancer .......... 550
Y. Feng and P.C. Ma
Commentary on Catenacci et al., p. 573

Genomic Investigation of Dedifferentiated Liposarcoma Suggests a Role for Therapeutic Targeting of the Tumor Epigenome .......... 555
P.S. Meltzer and L.J. Heilman
Commentary on Taylor et al., p. 587

A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Non–Small Cell Lung Cancer .......... 557
M. Rodríguez-Paredes and M. Esteller
Commentary on Juergens et al., p. 598

CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be? .......... 560
M. Ladanyi
Commentary on Cheung et al., p. 608

REVIEW
PI3Kα Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic .......... 562
D.A. Fruman and C. Rammel

RESEARCH BRIEFS
Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence .......... 573

Précis: An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with MET gene polysomy and autocrine HGF production.

A Novel Platform for Detection of CK⁺ and CK⁻ CTCs ............. 580

Précis: An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies nonepithelial CTCs.
Complete Response of Gastric Cancer with Anti-Met Therapy


Precis: Overexpression of the CRKL adaptor protein activates oncogenic signaling pathways and promotes drug resistance in NSCLC.

Corrections

Correction: Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium. .............. 626
Correction: Forty Years of Translational Cancer Research ........ 627
Correction: Drugs, Diagnostic Tests Approved Quickly. .............. 627
Acknowledgment to Reviewers ....... 628

For more News and Research Watch, visit Cancer Discovery online at www.AACR.org/CDnews. Online-only News stories include the following:

• HDAC Inhibitors Show Benefits in Breast Cancer
• Phenotypic Profiling Identifies Novel Anticancer Drugs
• Automated Pathology Gives Accurate Predictions
• Triple-Acting Drug Boosts Prostate Cancer Survival
• Analyzing Intact Proteins with Mass Spectrometry
• FDA Pulls Approval for Avastin in Breast Cancer

ON THE COVER

Juergens and colleagues present results from a phase I/II trial showing that combined epigenetic therapy with azacitidine and entinostat can elicit objective responses, including one complete and one partial response, in refractory metastatic non–small cell lung cancer (NSCLC). A decreased methylation signature in response to treatment was associated with longer overall and progression-free survival, indicative of on-target epigenetic effects. Furthermore, several patients had objective responses to subsequent anticancer therapies. This combination epigenetic therapy may therefore be effective in reversing the epigenetic mechanisms driving the progression and resistance of NSCLC. For details, please see the article by Juergens and colleagues on page 598.